Psychosomatic Medicine Tips for Better Browsing
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Freedman, R. R.
Right arrow Articles by Mayes, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Freedman, R. R.
Right arrow Articles by Mayes, M.

Psychosomatic Medicine, Vol 53, Issue 4 433-439, Copyright © 1991 by American Psychosomatic Society

ORIGINAL ARTICLES

Plasma catecholamines during behavioral treatments for Raynaud's disease

RR Freedman, D Keegan, P Migaly, MP Galloway and M Mayes
Lafayette Clinic, Detroit, MI 48207.

We have previously demonstrated that the vasospastic attacks of Raynaud's disease can be induced despite blockade of efferent digital nerves and that feedback-induced vasodilation is mediated through a non-neural, beta-adrenergic mechanism. Here, we sought to determine the role of sympathetic activity, as measured by plasma epinephrine and norepinephrine, during finger temperature feedback and autogenic training. Thirty-one female patients with idiopathic Raynaud's disease were randomly assigned to receive finger temperature feedback or autogenic training over 28 days. Half of each group began and finished training during the follicular phase of the menstrual cycle, the other half during the luteal phase. During training, significant temperature elevations were shown by feedback patients but not by autogenic patients. There were no significant effects for norepinephrine and epinephrine for either group. Cycle phase did not interact with training effects or with catecholamines. These findings do not support the role of decreased sympathetic activation in behavioral treatments for Raynaud's disease.


This article has been cited by other articles:


Home page
 Psychosom. Med.Home page
F. J. Keefe, M. A. Lumley, A. L. H. Buffington, J. W. Carson, J. L. Studts, C. L. Edwards, D. J. Macklem, A. K. Aspnes, L. Fox, and D. Steffey
Changing Face of Pain: Evolution of Pain Research in Psychosomatic Medicine
Psychosom Med, November 1, 2002; 64(6): 921 - 938.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
Raynaud's Treatment Study Investigators
Comparison of Sustained-Release Nifedipine and Temperature Biofeedback for Treatment of Primary Raynaud Phenomenon: Results From a Randomized Clinical Trial With 1-Year Follow-up
Arch Intern Med, April 24, 2000; 160(8): 1101 - 1108.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
J. Belch
Raynaud's phenomenon
Cardiovasc Res, January 1, 1997; 33(1): 25 - 30.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Psychosomatic Society